Matthew J. Ellis, MD, PhD

Matthew J. Ellis, MD, PhD, professor and director, Lester and Sue Smith Breast Center, associate director of precision medicine, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses adjuvant CDK4/6 inhibition in hormone receptor (HR)-positive breast cancer.

Matthew J. Ellis, MD, PhD, professor and director, Lester and Sue Smith Breast Center, associate director of Precision Medicine, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses considerations for the use of biosimilars in oncology.

Matthew J. Ellis, MD, PhD, professor and director, Lester and Sue Smith Breast Center, associate director of precision medicine, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses the entrance of biosimilars into the field of oncology.

Matthew J. Ellis, MD, PhD, professor and director, Lester and Sue Smith Breast Center, associate director of precision medicine, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses the use of abemaciclib (Verzenio) in hormone receptor-positive breast cancer.

Matthew J. Ellis, MD, PhD, professor and director, Lester and Sue Smith Breast Center, associate director of precision medicine, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses resistance to endocrine therapy in hormone receptor (HR)-positive breast cancer.

Matthew J. Ellis, MD, PhD, professor of oncology and medicine at Baylor College of Medicine, discusses developments with immunotherapy for patients with HER2-positive breast cancer.

Matthew J. Ellis, MD, PhD, professor of Oncology and Medicine at Baylor College of Medicine, discusses neoadjuvant endocrine therapy for patients with breast cancer.

Matthew Ellis, MD, PhD, director, Smith Breast Center, Baylor College of Medicine, discusses questions regarding the impact of CDK4/6 inhibitors in breast cancer.

Matthew J. Ellis, MD, PhD, from the Siteman Cancer Center, discusses the ongoing phase III FALCON trial.

Matthew J. Ellis, MD, PhD, professor, Department of Medicine, Oncology Division, Breast Oncology Section, Washington University School of Medicine in St. Louis, Missouri, discusses the future of The Cancer Genome Atlas project.

Dr. Matthew Ellis, from Siteman Cancer Center, on Heterogeneity Impacting Biomarker Efficacy

Dr. Matthew Ellis, from Siteman Cancer Center, Describes Breast Cancer Heterogeneity

Dr. Matthew Ellis from Washington University, St Louis, Discusses Genome Forward Breast Cancer Treatment

Dr. Matthew Ellis from Washington University on Anticipated ER-positive/HER2-negative Breast Cancer Paradigms

Dr. Matthew J. Ellis from Washington University on Measuring Endocrine Therapy Efficacy With Ki67

Dr. Matthew J. Ellis from Washington University Discusses Ki67 as a Treatment Monitoring Biomarker

Dr. Matthew J. Ellis from Washington University Discusses the Future of the PI3-Kinase Pathway

Dr. Matthew Ellis from Washington University Discusses the Cell-Proliferation Marker Ki67